22 December 2025
Grant of share options – mandatory notification of trade
Oslo, Norway, 22 December 2025: Oncoinvent ASA (“Oncoinvent” or the “Company”) (OSE: ONCOIN), a clinical stage, radiopharmaceutical company developing innovative treatments for solid cancers, today announce that the Board of Directors has granted options to employees.
As previously communicated and with the objective of aligning share option participants’ interests with those of the shareholders of the Combined Company, the Board of Directors has established a replacement share option and RSU program for employees and board members similar to Oncoinvent’s program before the merger with BerGenBio. This has been transformed by using the exchange ratio in the merger and adjusting the strike to secure a value neutral transition. Following this, a total of 6,355,096 share options has been granted as replacement for the previous option program, of which 4,451,133 to primary insiders. See the attached forms.
Options granted under the share option program will normally vest equally over a four-year period from the date of grant and each option, when exercised, will give the right to receive one share in the Company at a fixed strike price set at time of grant. Options granted under the share option program expire seven years after grant date.
In addition, a total of 25,770,000 new share options were granted, equal to 5.4% of fully diluted shares in the Company. Total options outstanding after this grant are 32,125,096, equal to 6.7% of fully diluted shares in the Company. The strike price for this grant is NOK 0.50 per option equal to the volume weighted average share price the last day before the grant, limited to nominal value of the shares. Of the total grant, 15,500,000 share options were granted to primary insiders of the Company (total holdings of share options following this grant and replacement program):
Øystein Soug – CEO: 5,000,000 (6,106,466)
Kari Myren – CMO: 2,000,000 (2,358,399)
Anne-Kirsti Aksnes – CCO: 2,000,000 (2,336,751)
Gro Hjellum – COO: 2,000,000 (2,334,826)
Kristine Lofthus – CPO: 1,500,000 (1,829,534)
Stian Brekke – Head of RA: 1,500,000 (1,828,813)
Anne Cecilie Alvik – Head of QA: 1,500,000 (1,828,452)
Share options issued to the board as part of the replacement option program following the merger:
Gillies O’Bryan-Tear (Chairperson of the Board): 353,722
Kari Grønås (Board member): 165,168
Hilde Steineger (Board member): 165,168
Orlando Oliveira (Board member): 165,168
Johan Häggblad (Board member): 95,012
The board considers an option program as an important element in attracting and retaining employees to foster long-term success. The board considers the option program terms and allocation to be at the market for comparable peers.
PDMR notifications of transactions: replacement options
PDMR notifications of transactions: new grants
This information is subject to the disclosure requirements pursuant to article 19 of the regulation EU 596/2014 (the EU Market Abise Regulation) and section 5-12 of the Norwegian Securities Trading Act.
About Oncoinvent
Oncoinvent is developing Radspherin®, a receptor-independent alpha radiation therapy that leverages the unique anatomy of the abdominal cavity to destroy residual micrometastases using a single, highly localized dose of alpha radiation. The initial clinical focus is treatment of ovarian and colorectal cancer patients after surgical removal of the primary tumor and visible metastases in the peritoneum, the thin membrane lining the abdominal cavity and covering the abdominal organs.
This radiopharmaceutical is designed to prevent or delay recurrence in the peritoneal cavity, keeping patients disease-free for longer than the current standard of care and thereby also impacting overall survival. It is broadly applicable to any cancer that spreads to the peritoneum, e.g. ovarian, colorectal, and gastric cancers. Radspherin® stands out for its simplicity, excellent safety profile, and seamless integration into existing surgical workflows. Oncoinvent’s product is easy to use, avoids systemic delivery and significant toxicity. It is also differentiated in being simple to manufacture, scalable, and supply de-risked.
Data from two trials in ovarian (phase 1) and colorectal (phase 1/2a) cancers, are highly promising, showing an excellent safety profile and meaningful signals of efficacy. Interim data from an ongoing, randomized, controlled phase 2 ovarian cancer trial is expected in 2026. With cost-effective manufacturing, blockbuster potential, active pharma partnership momentum, plus strong endorsements from leading experts, Oncoinvent is built for scale and commercial success, and is set to become the new standard for post-surgical cancer care. The Company was founded by the originators of Algeta and Xofigo (acquired by Bayer).
